testis expressed 15, meiosis and synapsis associatedGenealiases: CT42 · SPGF25
Q-omics provides the consensus-scored TEX15 profile across patient tissues and cancer cell-line models. TEX15 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, TEX15 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, TEX15 RNA expression shows 14,296 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LUAD, KIRC, and TGCT as cancer lineages where TEX15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TEX15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TEX15 survival associations across molecular data types. TEX15 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TEX15 RNA expression–survival associations across cancer types. High TEX15 expression shows unfavorable associations in LUAD, KICH, MESO, UVM and KIRP, but favorable associations in KIRC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for TEX15 RNA expression.
This table summarizes TEX15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TEX15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TEX15 shows lower tumor expression in COAD and higher tumor expression in KIRC, HNSC, LUAD, LUSC and KIRP. The KIRC box plot shows higher TEX15 RNA expression in tumor versus normal tissue (log2 FC = +1.346, t-test p < 0.001).
This table shows molecular features associated with TEX15 in patient tissues and cancer cell lines. In patient samples, TEX15 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TEX15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BONE.
